Does Xolair Work for Chronic Hives?
Xolair (omalizumab) is FDA-approved for chronic idiopathic urticaria (CIU), or chronic hives, in patients 12 years and older who remain symptomatic despite H1 antihistamine treatment.[1] Clinical trials show it reduces hive severity and itch. In two key phase 3 studies (ASTERIA I and II), patients on 300 mg doses every 4 weeks saw their weekly itch severity score drop by 66-68% and hive score by 64-68% at week 12, compared to 37-50% and 42-49% on placebo.[2][3]
How Quickly Does It Start Working?
Relief often begins within 2-4 weeks. In trials, about 50-65% of patients achieved complete hive resolution ( UAS7=0) by week 12 on 300 mg, versus 10-25% on placebo.[2][3] Real-world data confirms similar timelines, with many patients reporting less itching in days to weeks.[4]
Who Responds Best and What Doses Are Used?
It's most effective for moderate-to-severe cases unresponsive to antihistamines. Standard dose is 300 mg subcutaneously every 4 weeks; lower doses (150 mg) work for some but less reliably.[2] Approval covers ages 12+, with pediatric data showing 60-80% response rates.[5] Non-responders after 12 weeks rarely benefit from continuing.
What Do Studies Show Long-Term?
Up to 48 weeks of data from extension trials indicate sustained benefits, with 44-65% maintaining complete response without increased side effects.[6] No loss of efficacy over time in most patients.
Common Side Effects and Risks
Injection-site reactions (45%), headaches (20%), and sinusitis (16%) are typical. Anaphylaxis risk exists (0.1% per dose), requiring monitoring for 2 hours after the first few doses.[1] No increased infection risk in hives trials, unlike asthma use.
How Does It Compare to Other Treatments?
| Treatment | Response Rate (Complete Resolution) | Speed | Cost (Monthly, Approx.) |
|-----------|-------------------------------------|--------|-------------------------|
| Xolair (300 mg) | 50-65% at 12 weeks [2][3] | 2-4 weeks | $2,000-$3,000 [7] |
| High-dose antihistamines | 20-40% [8] | Days-weeks | <$50 |
| Cyclosporine | 50-70% [9] | 2-4 weeks | $100-$500 |
| Dupixent (dupilumab) | 30-45% (off-label) [10] | 4-12 weeks | $3,000+ |
Xolair outperforms antihistamines and avoids cyclosporine's kidney risks, but it's pricier and requires injections.
Is It Covered by Insurance and What's the Cost?
Most U.S. plans cover it for CIU with prior authorization, showing antihistamine failure. Patient copays range $0-$100/month via copay cards; list price nears $36,000/year.[7] No generic; patent expires around 2027-2030 per DrugPatentWatch.com.[11]
When Might It Not Work?
Up to 30-40% don't fully respond, possibly due to non-IgE pathways in their hives. Guidelines recommend stopping after 12-24 weeks if no improvement.[12] Not approved for acute hives or known triggers (e.g., allergies).
[1] FDA Label: Xolair (omalizumab), Genentech/Novartis, 2024.
[2] Maurer et al., N Engl J Med 2013; ASTERIA I trial.
[3] Saini et al., J Allergy Clin Immunol 2015; ASTERIA II trial.
[4] Bernstein et al., Ann Allergy Asthma Immunol 2018; real-world study.
[5] Hamilou et al., Pediatr Allergy Immunol 2021.
[6] Long-term GLACIAL trial, Fine et al., J Allergy Clin Immunol 2014.
[7] GoodRx pricing data, 2024.
[8] Zuberbier et al., Allergy 2018; EAACI guidelines.
[9] Grattan et al., Br J Dermatol 2007.
[10] Investigational data, Metz et al., J Allergy Clin Immunol 2022.
[11] DrugPatentWatch.com: Xolair patents.
[12] AAAAI/ACAAI guidelines, 2023.